Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Period
Forecast Period
Tight, that's the word for Cephalexin's regional spread all year, worth noting for a globally traded generic antibiotic. India edged out all of the other markets in the first half of 2026 (H1 2026), rising by 1.6% to a value of USD 52.31/KG in Q2 from USD 51.48/KG in Q1. The tighter export allocations out of India and Europe squeezed the availability elsewhere. The firm 7-ADCA feedstock costs added a second layer of pressure. Globally the picture barely moved, from a value of USD 51.48/KG to USD 52.31/KG, the same 1.6 percent. Expect a range of USD 52-57/KG for the second half of 2026 (H2 2026). The seasonal hospital restocking and the steady export demand keep things on the firmer side.
Cephalexin starts its life as 7-ADCA, a fermentation-derived intermediate. From there, it goes through the acylation with the phenylglycine derivatives, then the purification down to the pharmaceutical grade. A standard first-generation cephalosporin mechanism. It inhibits the bacterial cell wall synthesis, reaching a broad swath of the gram-positive organisms and some of the gram-negative ones too. Most of the volume goes toward the hospital and formulary procurement, treating the respiratory, skin, and urinary tract infections in tablet and oral suspension form. The export-led demand from the major pharmaceutical markets follows. A smaller veterinary formulation segment rounds it out. On the pricing side, the 7-ADCA and phenylglycine feedstock costs set the baseline. The coal-fired steam and environmental compliance costs stack on top of that. The timing of the seasonal hospital restocking determines the rest.
Heading into the second half of 2026 (H2 2026), the tone is modestly firm, not aggressive. The hospital and formulary buyers kept replenishing through the H1 on a fairly predictable seasonal respiratory prescription schedule, nothing unusual there. The feedstock costs for the 7-ADCA and phenylglycine held largely stable. The tighter export allocations from the usual suppliers kept a gentle floor under the market.
A disruption at a major fermentation facility, or tighter export restrictions out of India or Europe, would push things above the range of it. On the other side, a softer hospital procurement, or an easing of the current export constraints, would pull the prices below it.
| Region | 2026 Price Range (USD/KG) | Outlook |
| Global Average | 52 - 57 | Export allocation and hospital demand support |
| United States | 52 - 57 | Compliance expenses maintain firm pricing |
| China | 51 - 56 | Large fermentation capacity keeps pricing competitive |
| Germany | 52 - 57 | Steady formulary demand supports firm pricing |
| India | 52 - 58 | Tight export allocations support the highest premium |
Tighter export allocations from India and Europe were the real story in the US this quarter, not any domestic factor. The prices rose by 1.8% to a value of USD 52.50/KG. The distributors accelerated their seasonal replenishment on top of that, adding a bit more urgency to the move.
Why did the price of Cephalexin change in Q2 2026 in the United States?
Tighter export allocations from India and Europe cut into what was available to import. Distributors accelerated replenishment for seasonal demand and formulary updates. Firm 7-ADCA feedstock prices and compliance expenses were the backdrop against which all of it played out.
China rose by 1.3% to a value of USD 52.00/KG. A modest move, and it reflects the post-holiday restocking more than anything else. The export inquiries from India, Brazil, and Indonesia stayed firm all through the quarter.
Why did the price of Cephalexin change in Q2 2026 in China?
Post-holiday restocking activity picked up at fermentation facilities. Firm export inquiries from India, Brazil, and Indonesia kept demand consistent. Domestic hospital demand didn't move much either way, keeping the overall increase contained.
Germany's move was almost identical to the global average, up by 1.6% to a value of USD 52.30/KG. The steady formulary demand met the tighter European allocations, an unremarkable combination that still nudged the price higher.
Why did the price of Cephalexin change in Q2 2026 in Germany?
Steady formulary and hospital procurement kept the market ticking over normally. Tighter European allocations reduced merchant availability by a small margin. Compliance and testing expenses added a bit more on top.
India came out on top this quarter. A value of USD 52.60/KG, up by 1.9%, the highest of all four tracked markets. The tight export allocations are the reason, plain and simple. They constrained how much prompt supply was actually available in the market.
Why did the price of Cephalexin change in Q2 2026 in India?
Tight export allocations constrained prompt availability across the major supply routes. Firm 7-ADCA feedstock costs added a further layer of pressure on top. Strong demand from Nepal, Vietnam, and other export markets kept the increase going.
The US prices ticked up by 0.9% to a value of USD 51.55/KG. The tighter European allocations, and the firm 7-ADCA feedstock costs. Both in play, though neither dramatic on its own.
Why did the price of Cephalexin change in Q1 2026 in the United States?
Tighter European export allocations reduced import availability slightly. Firm 7-ADCA feedstock prices raised compliance and production costs at the same time. The result: a modest advance to USD 51.55/KG.
China's Q1 average landed at a value of USD 51.35/KG, up by about 1.1% from Q4. The steady operating rates at the Shanghai-area fermentation plants combined with the slightly firmer foreign inquiries. Nothing surprising for anyone watching this market closely.
Why did the price of Cephalexin change in Q1 2026 in China?
Steady operating rates at key fermentation facilities kept output consistent. Slightly firmer foreign inquiries from India and Brazil lifted export demand a touch. Public sector tenders resumed after the year-end holiday break, adding a bit more pull.
Germany rose by about 1.0% to a value of USD 51.50/KG in Q1, a small move driven by the steady hospital and formulary demand, not anything on the supply side.
Why did the price of Cephalexin change in Q1 2026 in Germany?
Steady hospital and formulary procurement kept demand consistent through the quarter. Compliance-related testing costs added a small amount of upward pressure. That combination set up the further gain that followed in Q2.
India rose by 1.2% to a value of USD 51.60/KG, the largest Q1 move among all four regions. The export demand from Nepal and other regional markets was the driver. The firming feedstock costs played a supporting role in it.
Why did the price of Cephalexin change in Q1 2026 in India?
Export demand from Nepal and other regional markets lifted procurement steadily through the quarter. Firming 7-ADCA feedstock costs pushed the underlying cost base up as well. Together, they laid the groundwork for the sharper rise in Q2.
A steady climb, with one notable acceleration, that's the pattern here. The global Cephalexin prices rose in every single one of the six tracked quarters, but the jump from Q3 2025 to Q4 2025 stands out at 3.4 percent, more than double any other quarter's move. From a value of USD 47.59/KG in Q1 2025 to USD 52.31/KG by Q2 2026, a gain of 9.9 percent over the full window. The seasonal hospital restocking cycles and the 7-ADCA feedstock cost trends explain most of the movement. That one sharper quarter ties back to an unusually strong late-year restocking.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 52.31 | +1.6% | ↑ Rising |
| Q1 2026 | 51.48 | +1.0% | ↑ Rising |
| Q4 2025 | 50.95 | +3.4% | ↑ Rising |
| Q3 2025 | 49.29 | +1.9% | ↑ Rising |
| Q2 2025 | 48.39 | +1.7% | ↑ Rising |
| Q1 2025 | 47.59 | - | - Stable |
A slow, steady grind upward, that was the year 2025 for Cephalexin, with the sharpest move landing right at the year-end. The global average opened at a value of USD 47.59/KG in Q1, closed the year at USD 50.95/KG, a gain of 7.1 percent. The seasonal respiratory prescription demand and the firming compliance costs across the major producing regions drove most of it. The biggest single-quarter jump came in Q4, on the back of an unusually strong restocking ahead of the new year.
The US prices moved from a value of USD 47.70/KG to USD 51.10/KG over the year, a gain of 7.1 percent, roughly matching the global average. The steady formulary demand, along with the firming compliance costs, both contributed.
China posted the smallest annual gain of all four regions, at 6.9 percent, from a value of USD 47.50/KG to USD 50.80/KG. The fermentation output stayed steady throughout, with the export demand providing the main upward push.
The German prices climbed by 7.1 percent, from a value of USD 47.60/KG to USD 51.00/KG, essentially tracking the global pattern. The hospital and formulary procurement stayed consistent all through the year.
India also gained by 7.1 percent, from a value of USD 47.60/KG to USD 51.00/KG. The export demand from Nepal, Vietnam, and Brazil was the recurring theme behind the year's growth.
Expert Market Research: Your Source for Real-Time Cephalexin Price Intelligence
Expert Market Research tracks the Cephalexin prices continuously, across every major producing and consuming region. The team traces the causation through the 7-ADCA and phenylglycine feedstock economics, the compliance cost cycles, and the shifting hospital and export-led demand. Contact Expert Market Research today for the Cephalexin pricing data, a bespoke market analysis, and a strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
The hospital and formulary procurement accounts for most of the demand, treating the respiratory, skin, and urinary tract infections in tablet and oral suspension form. The export-led demand from the major pharmaceutical markets and the veterinary formulation use make up the rest.
The Q2 2026 prices come to a value of USD 52.50/KG in the United States, USD 52.00/KG in China, USD 52.30/KG in Germany, and USD 52.60/KG in India. Worth noting how narrow that range actually is, as barely 60 cents separates the highest and lowest markets.
The global average moved from a value of USD 50.95/KG in Q4 2025 to USD 51.48/KG in Q1 2026, then to USD 52.31/KG by Q2, a gain of 1.6 percent across the half-year. The tighter export allocations, along with the firm feedstock costs, drove the increase.
The steady operating rates at the key fermentation facilities kept the output consistent even as the demand firmed. The slightly stronger foreign inquiries from India and Brazil added to the export pull. The public sector tenders resuming after the holiday break gave the market a final nudge.
A range of USD 52 to 57/KG is the likely one for the rest of the year 2026, assuming the seasonal hospital restocking and the export demand hold at their current pace.
Not by much, honestly, this is one of the tightest regional spreads in the entire generic antibiotic space. India carries a marginal premium tied to the export allocation tightness. The United States and Germany sit close behind, owing to the compliance costs. China trails only slightly, owing to the strength of its fermentation capacity.
Monthly. Reach out to the Expert Market Research team directly for real-time pricing intelligence.
The 7-ADCA and phenylglycine feedstock costs matter the most, with the coal-fired steam and environmental compliance costs at the fermentation facilities close behind. The seasonal hospital restocking cycles play a role too, and any change to the export allocation policy from India or Europe can shift the regional pricing fairly quickly.
China and India lead on the fermentation and semi-synthetic processing capacity, with Spain notable among the European producers. A shift in the 7-ADCA feedstock costs or the export allocation policy tends to show up across every single regional market.
Timing the hospital and formulary contracts around the seasonal respiratory prescription cycles helps. The 7-ADCA feedstock costs give the clearest early signal for where the production floor is heading, and watching the export allocation changes from India or Europe is worth the effort given how tightly this market trades.
Basic Report -
One Time
Basic Report -
Annual Subscription
Detailed Report -
One Time
Detailed Report -
Annual Subscription
Basic Report -
One Time
USD 799
tax inclusive*
Basic Report -
Annual Subscription
USD 3,499
tax inclusive*
Detailed Report -
One Time
USD 4,299
tax inclusive*
Detailed Report -
Annual Subscription
USD 7,999
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.